WallStreetZenWallStreetZen

NASDAQ: ACRV
Acrivon Therapeutics Inc Stock

$7.33-0.23 (-3.04%)
Updated Jul 19, 2024
ACRV Price
$7.33
Fair Value Price
$1.42
Market Cap
$226.33M
52 Week Low
$3.19
52 Week High
$13.20
P/E
-2.54x
P/B
2.1x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$64.12M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
-$48M
Beta
1.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ACRV Overview

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACRV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ACRV ($7.33) is overvalued by 415.87% relative to our estimate of its Fair Value price of $1.42 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ACRV ($7.33) is not significantly undervalued (415.87%) relative to our estimate of its Fair Value price of $1.42 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACRV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACRV due diligence checks available for Premium users.

Be the first to know about important ACRV news, forecast changes, insider trades & much more!

ACRV News

Valuation

ACRV fair value

Fair Value of ACRV stock based on Discounted Cash Flow (DCF)
Price
$7.33
Fair Value
$1.42
Overvalued by
415.87%
ACRV ($7.33) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACRV ($7.33) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACRV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ACRV price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.54x
Industry
-18.27x
Market
29.62x

ACRV price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.1x
Industry
6.22x
ACRV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ACRV's financial health

Profit margin

Revenue
$0.0
Net Income
-$16.5M
Profit Margin
0%
ACRV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$120.5M
Liabilities
$12.5M
Debt to equity
0.12
ACRV's short-term assets ($112.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACRV's short-term assets ($112.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACRV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$17.1M
Investing
$5.9M
Financing
-$172.0k
ACRV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ACRV vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ACRV$226.33M-3.04%-2.54x2.10x
ALDX$226.96M-1.29%-7.49x2.00x
CYBN$228.02M0.00%-1.65x1.07x
EPIX$228.03M-4.64%-8.16x1.71x
TSVT$229.78M-1.11%-1.03x1.11x

Acrivon Therapeutics Stock FAQ

What is Acrivon Therapeutics's quote symbol?

(NASDAQ: ACRV) Acrivon Therapeutics trades on the NASDAQ under the ticker symbol ACRV. Acrivon Therapeutics stock quotes can also be displayed as NASDAQ: ACRV.

If you're new to stock investing, here's how to buy Acrivon Therapeutics stock.

What is the 52 week high and low for Acrivon Therapeutics (NASDAQ: ACRV)?

(NASDAQ: ACRV) Acrivon Therapeutics's 52-week high was $13.20, and its 52-week low was $3.19. It is currently -44.47% from its 52-week high and 129.78% from its 52-week low.

How much is Acrivon Therapeutics stock worth today?

(NASDAQ: ACRV) Acrivon Therapeutics currently has 30,876,932 outstanding shares. With Acrivon Therapeutics stock trading at $7.33 per share, the total value of Acrivon Therapeutics stock (market capitalization) is $226.33M.

Acrivon Therapeutics stock was originally listed at a price of $16.64 in Nov 15, 2022. If you had invested in Acrivon Therapeutics stock at $16.64, your return over the last 1 years would have been -55.95%, for an annualized return of -55.95% (not including any dividends or dividend reinvestments).

How much is Acrivon Therapeutics's stock price per share?

(NASDAQ: ACRV) Acrivon Therapeutics stock price per share is $7.33 today (as of Jul 19, 2024).

What is Acrivon Therapeutics's Market Cap?

(NASDAQ: ACRV) Acrivon Therapeutics's market cap is $226.33M, as of Jul 22, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Acrivon Therapeutics's market cap is calculated by multiplying ACRV's current stock price of $7.33 by ACRV's total outstanding shares of 30,876,932.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.